Please assess the completion status of the following clinical trial:

Trial Title: Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 70 years.~* Histologically proven non-Hodgkin's lymphoma~* Relapse after achieving initial remission or failure to achieve initial remission.~* KPS \> 70%~* Matched related or unrelated donor identified and available. Donor must be a complete match or have only a single allele mismatch.~* Recent Bone marrow biopsy and cytogenetic analysis~* Patients must have a pretreatment serum bilirubin \< 2 x the institutional ULN, a serum creatinine \< 2 x the institutional ULN and measured or estimated creatinine clearance \> 50 cc/min by the following formula (all tests must be performed within 28 days prior to mobilization ): Estimated Creatinine Clearance = (140 age) X WT(kg) X 0.85 if female 72 X serum creatinine(mg/dl).~* Patients must have an EKG within 42 days prior to registration that shows no significant abnormalities that are suggestive of active cardiac disease.~* Patients must have an echocardiogram or MUGA scan within 42 days of registration. If the ejection fraction is \< 40%, the patient will not be eligible. If the ejection fraction is 40-50%, patients must have an exercise echocardiogram or dobutamine-echo with a normal response to exercise.~* Patients must have a corrected diffusion capacity \> 50% prior to the autologous transplant and \> 40% prior to the allogeneic transplant.~* Patients with known allergy to etoposide or a history of Grade 3 hemorrhagic cystitis with cyclophosphamide are not eligible.~* Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.~Exclusion Criteria:~* Pregnant or breast-feeding women are ineligible due to the known birth defects association with the treatments used in this study.~* Patients known to be human immunodeficiency virus (HIV)-positive are ineligible because the concern for opportunistic infection and hematologic reserve are considered to be significantly greater in this population.~* Patients with prior maligancies diagnosed \> 5 years ago without evidence of disease are eligible. Patients with a prior malignancy treated \< 5 years ago but have a life expectancy of \> 5 years for that malignancy are eligible.~* Patients with uncontrolled infection.~* No prior autologous or allogeneic hematopoietic cell transplantation.~Donor Selection/Evaluation:~* Related or unrelated HLA identical donors who are in good health and have no contra-indication to donation.~* No contra-indication for the donor to collection by apheresis of mononuclear cells mobilized by G-CSF at a dose of 16 µg/kg of body weight.~* Virology testing including CMV, HIV, EBV, HTLV, RPR, Hepatitis A, B and C will be performed within 30 days of donation.~* No prior malignancy is allowed except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer or other cancer for which the donor has been disease-free for five years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- T & B Cell Mobilization Auto & Allo HCT (Type: EXPERIMENTAL): A transplant regimen that conditions the subjects using total lymphoid irradiation (TLI) and anti-thymocyte globulin(ATG) which will reduce acute graft-vs-host disease to negligible rates while maintaining the anti-tumor graft vs lymphoma GvL benefit. Along with TLI/ATG regiment; Solumedrol will be used as pre-medication and anti-emetic for any side effects. For stem cell mobilization, participants will be given either B Cell NLH or T Cell NHL. Before the filgrastim (G-CSF) mobilized PBPC infusion: acetaminophen, diphenhydramine and hydrocortisone will also be given as another set of pre-medications. BCNU, Etoposide, and Cyclophosphamide will be used as a preparative regimen. Cyclosporine and mycophenolate mofetil will be administered as an immunosuppressant after transplantation. Lastly, rituximab will be infused at the end of the transplantation regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).